Venous Stasis Ulcer Clinical Trial
Official title:
A Randomized Trial of the Flexitouch Compression System as an Adjunctive Treatment for Venous Stasis Ulcer
The researchers hypothesize that utilization of the Flexitouch system will improve the
healing rates of (venous stasis ulcers) VSU compared to traditional compression wrapping
therapy alone.
Primary Objective: The primary study objective is to determine whether the complete healing
rate of venous stasis ulcers at 12 weeks is improved by the addition of Flexitouch® System
compression therapy to a standard regimen of compression wrapping.
Secondary Objectives:
- To determine whether the addition of Flexitouch System compression therapy to a
standard regimen of compression wrapping increases the percentage reduction in wound
surface area.
- To determine whether the addition of Flexitouch compression therapy to a standard
regimen of compression wrapping increases the percentage reduction in volume of the
affected limb.
- To determine whether the addition of Flexitouch compression therapy to a standard
regimen of compression wrapping decreases the time to healing of the venous stasis
ulcer.
Background:
Overview of venous stasis ulcers (1-3): Venous stasis ulceration is a common complication of
venous insufficiency in the United States. Venous stasis ulcers (VSU) are associated with
very significant morbidity, including patient disability, moderate to severe pain, and
frequent leg infections. There is also a large cost associated with the medical care needed
for this condition and the inability of patients to work. In some patients, this condition
can be life- or limb-threatening.
Current standard of care for VSU: It is widely accepted that VSU should be treated by an
individualized program of compression wrapping therapy (3-5). This therapy is designed to
counteract the presumed pathophysiology of VSU, which develop as a result of valvular reflux
and venous hypertension. However, the efficacy of compression therapy alone is suboptimal,
with healing rates of roughly 34% reported after 12 weeks of therapy (6). Various adjunctive
treatments have been studied, including artificial skin grafts (6-8). However, none of these
adjunctive modalities have become widely accepted for the treatment of VSU.
Potential role of compression pumps: Intermittent sequential compression pumps are widely
used as an adjunctive modality in the treatment of VSU. These pumps use high compression and
are expensive, but this expense may be outweighed by improved healing of VSU. The use of
compression pumps is consistent with the pathophysiology of VSU, but data regarding the
efficacy of such therapy is scarce. To date, no study has adequately assessed the efficacy
of compression pump therapy in the treatment of VSU (9).
Flexitouch System: The Flexitouch System was designed by a therapist trained in manual
lymphatic drainage therapy and is produced by Tactile Systems Technology, Inc. The
Flexitouch System was designed to simulate MLD techniques and is intended for home use
during the self-management phase of CDT. MLD is one (of four) component(s) of Complete
Decongestive Therapy, considered the "Gold Standard" for treatment of lymphedema. MLD is a
gentle, manual technique producing very light directional pressure/stretch on the skin with
manipulation of healthy lymph nodes and vessels. The effects of properly applied MLD include
increased intake of lymphatic loads into the lymphatic system, increased
lymphangiomotoricity, increased volume of transported lymph fluid, increased venous return
in the superficial venous system, promotion of parasympathetic response and pain control.
Treatment is always initiated at the trunk segments, with decongestion of proximal areas,
prior to addressing the involved extremity (to clear central areas and promote decongestion
of more distal areas). The extremity is then treated in segments, starting with the proximal
segments and then progressing from distal to proximal regions. The Flexitouch® System is not
intended to replace the intensive phase of CDT. However, it follows the principles of MLD in
many ways. Flexitouch system provides limb treatment, but in addition, it addresses trunk
congestion. The lower extremity garment set consists of two garments, one garment fits over
the affected lower extremity and the other fits over the lower abdomen/trunk. Each garment
is made up of multiple inflatable chambers within a flexible, stretchable fabric. The
treatment consists of a 2-phase program. As in MLD, the preparation phase begins the
treatment starting at the inguinal quadrant. Each curved trunk chamber inflates and deflates
sequentially to facilitate the movement of edema fluid into the systemic circulation. The
cycle is repeated several times. The inflation/deflation cycle is then repeated in each limb
region from the knee to the groin, from the ankle to the knee, and finally from the toes to
the ankle. The second phase, drainage, begins the sequential inflation/deflation cycle at
the toes and continues moving up the leg to the quadrant of the trunk to facilitate the
movement of edema fluid from the inguinal quadrant into the system circulation.
Choice of compression pump device for study of VSU treatment: A variety of inflatable
compression pumps are available, but there are no data to help choose among these devices
(9). No compression device is accepted as a standard of care for VSU. Flexitouch system
differs from standard (intermittent sequential) compression pumps in significant ways. As
described above, Flexitouch system is unique as a compression device, because it provides
not only sequential limb compression, but also trunk compression. Flexitouch system's
two-phase program (preparation and drainage) also makes it different from other compression
devices. The fact that the system was created for lymphedema may be an advantage in the
treatment of VSU, because many authors (10;11) believe that secondary lymphedema plays an
important role among VSU patients.
Study Outline:
Patient enrollment procedure
- An approved consent form and authorization permitting release of personal health
information must be signed by the patient or guardian.
- All eligibility requirements indicated in Section 3.0 must be satisfied.
- The patient must be registered by calling the study coordinator Lisa Rudman, at
Allegheny General Hospital (412-359-4325).
General treatment plan: After enrollment, all patients will be seen once per week for a
12-week period for standard compression wrapping. At each visit, treatment and assessment
will be undertaken as described below. The Flexitouch group only will use the Flexitouch
System both at home (once daily) and in-clinic (once per week).
Essential elements of treatment and assessment:
Applicable to ALL patients
- The patients will be seen at the wound center one(1) times per week for 12 weeks.
- Patients will receive compression wrapping as standard of care therapy. The precise
amount of compression will be individualized according to patient tolerance using 3M
Coban 2 layer Compression System.
- The wound area will be measured and photographed weekly, using wound tracing and
planimetry software.
- The limb volume will be measured weekly, using available software (NetHealth,
Pittsburgh PA).
- The presence or absence of wound infection will be assessed. The need for wound
debridement will be recorded.
- The wound will be scored as to whether or not it has healed. If the wound healed at a
previous visit, the presence of recurrent ulceration will be assessed.
- The occurrence of treatment failure will be recorded (see section 7d).
- Comprehensive standard wound care treatment including gentle wound cleansing with
saline solution at each visit, maintaining moisture balance in the wound and periwound
with appropriate dressings (alginate, foam, hydrogel or hydrocolloid), reminding
subjects of the importance of proper nutrition, leg elevation at rest and activity,
including frequent ambulation and ankle ROM exercises through the day.
Additional steps applicable to patients randomized to Flexitouch arm:
- Patients will be provided a home Flexitouch unit. They will be given instructions to
use the Flexitouch system on a once daily basis. They will not need remove the
compression wrap for the home therapy.
- In addition to the home use, at each clinic visit, the patient's trunk and affected
limb will be treated for 60 minutes with the Flexitouch system.
- The patient will be asked to indicate their level of comfort with the in-clinic
Flexitouch session (scale of 0 to 5; 0 = very comfortable, 5 = very uncomfortable).
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01853384 -
Safety and Efficacy Trial of HP802-247 in the Treatment of Chronic Venous Leg Ulcers
|
Phase 3 | |
Enrolling by invitation |
NCT02813187 -
Venous Leg Ulcer and Lymphedema Registry
|
||
Completed |
NCT03881267 -
SkinTE® in the Treatment of Venous Leg Wounds
|
N/A | |
Terminated |
NCT01612806 -
A Multi-center, Prospective, Randomized Study With PriMatrix and PriMatrix Ag for the Treatment of Venous Leg Ulcers
|
N/A | |
Terminated |
NCT01376050 -
Efficacy Study of the Application of Low Level Laser Light to Treat Venous Stasis Ulcers
|
N/A | |
Completed |
NCT00900029 -
Safety Follow-Up to HP 802-247-09-015
|
N/A | |
Completed |
NCT02626156 -
Cooling Leg and Foot Ulcer Skin Post Healing to Prevent Ulcer Recurrence
|
Phase 2 | |
Recruiting |
NCT02467998 -
Negative Pressure Wound Therapy Registry
|
||
Recruiting |
NCT02322554 -
Cellular and Tissue Based Therapy Registry
|
||
Recruiting |
NCT04647240 -
Dermacyte® Amniotic Wound Care Liquid for the Treatment of Non-Healing Venous Stasis Ulcers
|
Phase 2 | |
Completed |
NCT02395302 -
Evaluation of a Dual Action Pneumatic Compression System: Tolerance and Comfort in Patients With Venous Leg Ulcers
|
N/A | |
Completed |
NCT00270946 -
Evaluation of Bilayered Cellular Matrix (OrCel) for the Treatment of Venous Ulcers
|
N/A |